NUTRA PHARMA CORP. Accrued Liabilities for Commissions, Expense and Taxes
NUTRA PHARMA CORP. (NPHC) had Accrued Liabilities for Commissions, Expense and Taxes of $142.50 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Financial Services
us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes · last filed 2026-08-19
- 2026-06-30: Accrued Liabilities for Commissions, Expense and Taxes $142.50K.
- 2026-03-31: Accrued Liabilities for Commissions, Expense and Taxes $142.50K.
- 2025-12-31: Accrued Liabilities for Commissions, Expense and Taxes $142.50K.
- 2025-09-30: Accrued Liabilities for Commissions, Expense and Taxes $142.50K.
| Period end | Accrued Liabilities for Commissions, Expense and Taxes |
|---|---|
| 2026-06-30 | $142.50K 10-Q · filed 2026-08-19 |
| 2026-03-31 | $142.50K 10-Q · filed 2026-05-29 |
| 2025-12-31 | $142.50K 10-Q · filed 2026-08-19 |
| 2025-09-30 | $142.50K 10-Q · filed 2026-04-06 |
| 2025-06-30 | $142.50K 10-Q · filed 2026-03-25 |
| 2025-03-31 | $142.50K 10-Q · filed 2026-03-11 |
| 2024-12-31 | $142.50K 10-K · filed 2026-05-20 |
| 2024-09-30 | $142.50K 10-Q · filed 2026-01-02 |
| 2024-06-30 | $142.50K 10-Q · filed 2025-12-23 |
| 2024-03-31 | $142.50K 10-Q · filed 2025-12-17 |
| 2023-12-31 | $142.50K 10-K · filed 2026-02-17 |
| 2023-09-30 | $142.50K 10-Q · filed 2025-10-28 |
| 2023-06-30 | $142.50K 10-Q · filed 2025-10-23 |
| 2023-03-31 | $142.50K 10-Q · filed 2025-10-16 |
| 2022-12-31 | $142.50K 10-K · filed 2025-11-24 |
| 2022-09-30 | $142.50K 10-Q · filed 2022-11-21 |
| 2022-06-30 | $142.50K 10-Q · filed 2022-08-22 |
| 2022-03-31 | $142.50K 10-Q · filed 2022-05-20 |
| 2021-12-31 | $142.50K 10-K · filed 2022-04-15 |
| 2021-09-30 | $142.50K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $142.50K 10-Q · filed 2021-09-24 |
| 2021-03-31 | $142.50K 10-Q · filed 2021-09-17 |
| 2020-12-31 | $142.50K 10-K · filed 2021-09-08 |
| 2020-09-30 | $142.50K 10-Q · filed 2021-08-12 |
| 2020-06-30 | $142.50K 10-Q · filed 2021-08-05 |
| 2020-03-31 | $142.50K 10-Q · filed 2021-07-23 |
| 2019-12-31 | $142.50K 10-Q · filed 2021-08-12 |
| 2019-09-30 | $142.50K 10-Q · filed 2021-05-14 |